Immune System Modulation by Low-dose Ionizing Radiation-induced Adaptive Response
Overview
Pathology
Pharmacology
Authors
Affiliations
Objective: Hormesis or low-dose ionizing radiation is known to induce various biological responses, a subcategory of which is the adaptive response, which has been reported to protect against higher radiation doses via multiple mechanisms. This study investigated the role of the cell-mediated immunological component of low-dose ionizing radiation-induced adaptive response.
Methods: Herein, male albino rats were exposed to whole-body gamma radiation, using a Cs source with low-dose ionizing radiation doses of 0.25 and 0.5 Gray (Gy); 14 days later, another irradiation session at a dose level of 5 Gy was carried on. Four days post-irradiation at 5 Gy, rats were sacrificed. The low-dose ionizing radiation-induced immuno-radiological response has been assessed through the T-cell receptor (TCR) gene expression quantification. Also, the serum levels of each of interleukins-2 and -10 (IL-2, IL-10), transforming growth factor-beta (TGF-β), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) were quantified.
Results: Results indicated that priming low irradiation doses resulted in significant decrements in TCR gene expression and the serum levels of IL-2, TGF-β, and 8-OHdG with an increment in IL-10 expression compared to the irradiated group, which did not receive low priming doses.
Conclusion: The observed low-dose ionizing radiation-induced radio-adaptive response significantly protected against high irradiation dose injuries, through immune suppression, representing a promising pre-clinical protocol that would be applied to minimize radiotherapy side effects on normal but not against the tumor cells.
Yin J, Ye Y, Gao Y, Xu Q, Su M, Sun S Int J Mol Sci. 2025; 26(5).
PMID: 40076897 PMC: 11900348. DOI: 10.3390/ijms26052269.
Alzheimer's disease and low-dose radiation therapy: A new hope.
Dunlap N, Friedland R, Cai L Radiat Med Prot. 2024; 5(1):1-6.
PMID: 38585336 PMC: 10997373. DOI: 10.1016/j.radmp.2024.01.002.
A new target of radiotherapy combined with immunotherapy: regulatory T cells.
Song D, Ding Y Front Immunol. 2024; 14:1330099.
PMID: 38259489 PMC: 10800811. DOI: 10.3389/fimmu.2023.1330099.
Zhu J, Li C, Wang P, Liu Y, Li Z, Chen Z MedComm (2020). 2023; 4(5):e366.
PMID: 37706195 PMC: 10495731. DOI: 10.1002/mco2.366.